The study provides a nearly complete parts list of all the machines in yeast, including 257 previously unknown machines and new components of existing ones. It also reveals how cells dynamically assemble and disassemble machines to respond to environmental challenges.
GlycoFi researchers have made a major leap in protein bioengineering by controlling sugar structures on antibodies to boost cancer-killing ability. This approach can be applied to any therapeutic glycoprotein, and the company is poised to capitalize on the growing 20% annual growth of the therapeutic protein market.
Researchers have discovered a way to multiply adult stem cells 30-fold, offering promise for treating blood diseases and gene therapies. This breakthrough could address the limited availability of stem cells from donors.
U of MN researchers identified the specific mutation causing Spinocerebellar ataxia type 5 (SCA5), a dominant gene disorder. The discovery enables genetic testing for patients at risk, providing improved diagnoses and insight into neurodegenerative diseases.
Researchers found that up to 25% of injected malaria parasites stop in lymph nodes close to the bite site, where they can interact with immune cells and degrade. While partially developed or destroyed parasites may not contribute to symptoms, their presence could affect how the immune system responds to infection.
Researchers at GlycoFi have successfully produced human-glycosylated antibodies in yeast, improving cell killing and drug characteristics. This breakthrough allows for unprecedented control and uniformity of glycosylation, enabling optimization of therapeutic proteins.
Researchers created a modified form of troponin I to improve cardiac function in mice and damaged human heart cells. The protein helps the heart respond to stress by boosting performance during periods of hardship.